The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus.

MLA

Chang, L. H., et al. “The Combination of Soluble Tumor Necrosis Factor Receptor Type 1 and Fibroblast Growth Factor 21 Exhibits Better Prediction of Renal Outcomes in Patients with Type 2 Diabetes Mellitus.” Journal of Endocrinological Investigation, vol. 44, no. 12, Dec. 2021, pp. 2609–19. EBSCOhost, https://doi.org/10.1007/s40618-021-01568-7.

APA

Chang, L.-H., Hwu, C.-M., Chu, C.-H., Lin, Y.-C., Huang, C.-C., You, J.-Y., Chen, H.-S., & Lin, L.-Y. (2021). The combination of soluble tumor necrosis factor receptor type 1 and fibroblast growth factor 21 exhibits better prediction of renal outcomes in patients with type 2 diabetes mellitus. Journal of Endocrinological Investigation, 44(12), 2609–2619. https://doi.org/10.1007/s40618-021-01568-7

Chicago

Chang, L.-H., C.-M. Hwu, C.-H. Chu, Y.-C. Lin, C.-C. Huang, J.-Y. You, H.-S. Chen, and L.-Y. Lin. 2021. “The Combination of Soluble Tumor Necrosis Factor Receptor Type 1 and Fibroblast Growth Factor 21 Exhibits Better Prediction of Renal Outcomes in Patients with Type 2 Diabetes Mellitus.” Journal of Endocrinological Investigation 44 (12): 2609–19. doi:10.1007/s40618-021-01568-7.